What changed
Lilly reported TRANSCEND-T2D-2 topline results comparing retatrutide with Ozempic in adults with type 2 diabetes over 80 weeks.
What the evidence does not settle
The specified comparator does not represent every semaglutide product or population. Sponsor topline is not full-paper review or approval.
Evidence record
Event date: 2026-10-28. Source review: inherited source synthesis; not re-audited in this expansion. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.
Revision history
29 October 2026: migrated from the research edition, retaining source links and evidence qualifications; not re-audited in the current expansion. Report a proposed correction through Contact us; do not include patient data.